AOD-9604 vs Semaglutide
Metabolic
AOD-9604
C-terminal fragment of human growth hormone studied for lipolytic activity without the growth-promoting effects of the full hormone.
Metabolic
Semaglutide
Long-acting GLP-1 receptor agonist studied extensively for incretin pathway signaling and glucose regulation in preclinical models.
Side by side
| Dimension | AOD-9604 | Semaglutide |
|---|---|---|
| Molecular weight A 2.3× difference in mass — these are not comparable on a milligram-for-milligram basis. | 1815.08 g/mol | 4113.58 g/mol |
| Size class | mid-length peptide | long peptide |
| CAS number | 221231-10-3 | 910463-68-2 |
| Research area | metabolic | metabolic |
| Sequence | Not published as a linear sequence | Not published as a linear sequence |
| Available sizes | 5mg | 5mg, 10mg, 20mg |
| Entry price | $44 | $44 |
| Cost per mg | $8.80 | $6.45 |
Mechanism
AOD-9604
AOD-9604 corresponds to residues 176-191 of human growth hormone, the C-terminal region associated in early work with the hormone's effects on adipose tissue. The research premise is separation of function: retaining lipolytic activity while excluding the IGF-1-mediated growth signaling of full-length hGH. Published human trial results have been considerably more modest than the preclinical rodent data suggested — a gap worth knowing before designing around it.
Semaglutide
Semaglutide is a 31-amino-acid GLP-1 analog structurally modified at position 8 (Aib substitution) to resist DPP-4 degradation, with a C18 fatty diacid chain conjugated via a spacer at Lys26 that promotes albumin binding. These modifications extend its half-life substantially relative to native GLP-1, which has a circulating half-life measured in minutes. It is among the most heavily published peptides in modern metabolic research.
Evidence quality
Mechanism is not the same as evidence. Where we have assessed the literature, the verdict is stated plainly.
Semaglutide
Evidence base: extensive, independently replicated, with published receptor-level and pharmacokinetic characterization.
Full research reference →Research applications
AOD-9604
- Lipolysis and β-adrenergic pathway assays in adipocyte culture
- Comparative studies against full-length hGH
- IGF-1 independence verification studies
Semaglutide
- Incretin receptor signaling and β-cell response studies
- Gastric emptying and satiety-pathway research in rodent models
- Comparative pharmacokinetics against dual and triple agonists
- Receptor binding affinity and selectivity assays
Common questions
What is the difference between AOD-9604 and Semaglutide?
AOD-9604 is c-terminal fragment of human growth hormone studied for lipolytic activity without the growth-promoting effects of the full hormone. Semaglutide is long-acting GLP-1 receptor agonist studied extensively for incretin pathway signaling and glucose regulation in preclinical models. They differ in molecular weight (1815.08 vs 4113.58 g/mol) and in the pathways they are studied against.
Which is more cost-effective per milligram, AOD-9604 or Semaglutide?
Semaglutide is lower at approximately $6.45 per milligram at its best tier, against $8.80 for the other. Cost per milligram is only meaningful relative to the concentrations a given protocol requires, since these compounds are not used at comparable masses.
Can AOD-9604 and Semaglutide be studied together?
Combination designs appear in the published literature for a number of these compounds. Whether it is appropriate for a given protocol depends entirely on the model and endpoint. We supply research compounds and do not provide protocol guidance — consult the primary literature for your specific model.
How should AOD-9604 and Semaglutide be stored?
Store lyophilized at -20°C protected from light. Reconstituted at 2-8°C for up to 30 days. For Semaglutide: Store lyophilized powder at -20°C protected from light. Reconstituted solution is stable at 2-8°C for up to 30 days.
Which has the stronger evidence base?
Semaglutide — Evidence base: extensive, independently replicated, with published receptor-level and pharmacokinetic characterization. Where we have not published a formal evidence assessment, treat the literature as requiring your own appraisal.
All products are intended strictly for laboratory research use. Not for human or veterinary use. Not for diagnostic or therapeutic use. Not a drug, food, or cosmetic.
Comparison generated from NuVida Vital catalog data. Every specification is reconciled against the certificate of analysis for the shipped batch.